CATO SMS Acquires Nuventra to Add Clinical Pharmacology Capabilities
May 26, 2021
CATO SMS has acquired Nuventra, a Durham, North Carolina–based clinical pharmacology science and services provider, to expand its drug development offering into clinical pharmacology, pharmacometrics and model‑informed drug development. The deal brings Nuventra's PK/PD, population PK/PD and biosimulation expertise into CATO SMS's existing regulatory, biostatistics and clinical trial services to reduce development risk, cost and timelines for biopharmaceutical clients.
- Buyers
- CATO SMS
- Targets
- Nuventra, Inc.
- Industry
- Healthcare Services
- Location
- North Carolina, United States
- Transaction Type
- Buyout
Explore More
Related Acquisitions
-
Inceptua Group Acquires SupplyRx to Expand Clinical Trial Pharmacy Services
September 2, 2026
Healthcare Services
Inceptua Group, backed by Vesey Street Capital Partners, announced it has acquired SupplyRx, a U.S.-based technology-driven provider of cloud-based digital solutions for clinical trial pharmacy programs in the U.S. and Canada. The acquisition is intended to strengthen Inceptua’s pharmacy model by adding SupplyRx’s portal technology, networks, and processes to improve the clinical supply chain and patient access.
-
Sygnature Discovery Acquires NuChem Sciences
August 1, 2023
Biotechnology
UK-based integrated drug discovery CRO Sygnature Discovery has acquired Montreal-headquartered NuChem Sciences, one of North America's largest discovery contract research organisations. The deal expands Sygnature's global footprint and capabilities in medicinal chemistry, DMPK, structural biology and in vitro/in vivo pharmacology, strengthening its position in the North American market.
-
Novartis Acquires Cadent Therapeutics
December 17, 2020
Biotechnology
Novartis has entered an agreement to acquire Cadent Therapeutics, a Cambridge, Massachusetts–based clinical‑stage neuroscience company, adding two clinical‑stage programs for schizophrenia and movement disorders plus the buyout of MIJ821 milestones/royalties. The deal (reported up to $770 million including milestones) strengthens Novartis' neuropsychiatry portfolio and is expected to close in Q1 2021 subject to customary conditions.
-
CATO SMS Acquires Array Biostatistics
September 15, 2020
Healthcare Services
CATO SMS has acquired Wilmington, North Carolina–based Array Biostatistics to expand its biostatistical consulting, analysis and statistical programming capabilities. The acquisition is an add-on to the PE-backed CATO SMS platform and aims to broaden CATO SMS’ biometrics offering for small and emerging biopharmaceutical clients, particularly in oncology, rare/orphan indications and cell & gene therapy.
-
Cato Research Merges With SMS-oncology to Form CATO SMS
October 28, 2019
Healthcare Services
Cato Research, LLC has merged with Specialized Medical Services-oncology BV (SMS-oncology); the combined company will transition to the name CATO SMS. The deal expands Cato's oncology and regulatory capabilities and broadens the combined company's presence across Europe and North America; financial terms were not disclosed.
-
Sterling Pharma Solutions Acquires CiVentiChem US Facility in Cary, North Carolina
April 3, 2019
Pharmaceuticals
UK-based CDMO Sterling Pharma Solutions, a portfolio company of GHO Capital, has acquired the CiVentiChem US facility in Cary, North Carolina to establish a local presence for its North American clients and expand its chemistry development and kilo-scale cGMP capabilities. The acquisition supports Sterling’s strategy to build a global chemistry services business and follows GHO Capital’s majority investment in Sterling earlier this year.
Build a buyer list for your deal
Find active buyers from recent acquisition patterns and move straight into outreach.